CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / ELI Lilly & CO (LLY) / retatrutide
Forward catalyst · LLY

retatrutide

Sponsor ELI Lilly & CO · listed as LLY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

retatrutide is a clinical-stage drug asset sponsored by ELI Lilly & CO, listed as LLY. CSA tracks 4 forward catalysts for it — the nearest is a readout expected Aug 2026 (month precision, medium confidence), tied to trial NCT06260722. The asset is in Phase 3 and currently active not recruiting, studied in Diabetes Mellitus, Type 2. It appears across 11 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-08-31
As disclosedAug 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06260722
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorEli Lilly and Company
Listed asLLY
Condition(s)Diabetes Mellitus, Type 2

All tracked catalysts for retatrutide

DateEventConfidenceTrial
2026-08-31READOUTmediumNCT06260722
2026-10-31READOUTmediumNCT06297603
2026-12-31READOUTmediumNCT06662383
2027-07-31READOUTmediumNCT07232719
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More LLY catalysts